Zinbryta risks outweigh benefits, European report

Multiple sclerosis treatment Zinbryta was withdrawn in March and now a review by the European Medicines Agency has found its risks outweigh its benefits. The review confirms the drug’s association with the risk of developing severe and potentially fatal immune reactions in the brain, liver and other organs. It was carried out by to the … Continue reading Zinbryta risks outweigh benefits, European report

Drugs, risks, spending cuts, deaths, new drugs, and so much more

As we reach the start of another year, it seems a good time for me to review the last 12 months, as seen through the eyes of 50shadesofsun.com. January The year began by focusing on hematopoietic stem cell transplantation (HSCT). Dr Denis Fedorenko of the HSCT centre in Moscow published a guide to the procedure. … Continue reading Drugs, risks, spending cuts, deaths, new drugs, and so much more

HSCT Is a Controversial MS Therapy. Would You Have It? I’ve Decided!

There is little doubt that HSCT is controversial as a treatment, and some even say a cure, for multiple sclerosis. Some talk of great benefits; others feel the risks involved are too high. Then again, if you look at the side effects listed for the various disease modifying therapies (DMTs), they can be frightening, with death … Continue reading HSCT Is a Controversial MS Therapy. Would You Have It? I’ve Decided!